Notice of Proposed Sale · 144
Werewolf Therapeutics, Inc.
HOWLNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Werewolf Therapeutics, Inc.
- Issuer CIK
- 0001785530
- SEC file number
- 001-40366
- Phone
- 6179520555
- Person for whose account securities are to be sold
- MPM Asset Management LLC
- Relationships to issuer
- Shareholder
- Street
- 200 Talcott Avenue
- Street (continued)
- 2nd Floor
- City
- Watertown
- State / country code
- MA
- Postal code
- 02472
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 15,341 | 5,222.08 | 48,596,817 | 07/06/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 555 California Street
- Street (continued)
- 18th Floor
- City
- San Francisco
- State / country code
- CA
- Postal code
- 94104
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 05/04/2021 | Private Placement | Issuer | 15,341 | N | 05/04/2021 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Please see attached for securities sold over the last 3 months
Notice signature
- Notice date
- 07/06/2026
- Signed
- Kristen Laguerre
- Plan adoption dates
- 03/26/2026
Filed exhibits
- EX-99 ↗howl_tableiix20260706.pdf
Company context
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company has designed conditionally activated INDUKINETM molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. To learn more visit www.werewolftx.com.